Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
11026016 | Prostaglandins & Other Lipid Mediators | 2018 | 14 Pages |
Abstract
Drugs antagonizing the CysLT1 receptor, termed lukasts and typified by montelukast, are established therapeutics for clinical management of asthma. Lukasts are safe, well-tolerated drugs that can be administered during long time periods. Here we describe recent data indicating that montelukast may be used for prevention and treatment of AAA, thus representing a promising pharmacological tool for a deadly vascular disease with significant socio-economic impact.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Ana Carolina Araújo, Xiao Tang, Jesper Z. Haeggström,